Barbara E K Klein1, Ronald Klein, Kristine E Lee, Lisa M Grady. 1. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA. kleinb@epi.ophth.wisc.edu
Abstract
CONTEXT: Statins are widely prescribed for their lipid-lowering effects but also have putative antioxidant properties. Oxidative stress is believed to play a role in the development of nuclear cataract, but little is known regarding the relationship of statin use and cataract incidence. OBJECTIVE: To evaluate the relationship of use of statins and incident cataract in adults in a midwestern community in the United States. DESIGN, SETTING, AND PARTICIPANTS: The Beaver Dam Eye Study, an observational, longitudinal, population-based study of age-related eye disease in Beaver Dam, Wis. There were 1299 persons who were seen at the third examination in 1998-2000, had gradable photographs in both eyes, and were deemed to be at risk of developing nuclear cataract within 5 years. MAIN OUTCOME MEASURE: Five-year incidence of cataract with respect to statin use. Cataracts were graded from photographs taken through the participant's dilated pupil. RESULTS: A total of 210 persons developed incident nuclear cataract in the interval from 1998-2000 to 2003-2005. Five-year incidence of nuclear cataract was 12.2% in statin users compared with 17.2% in nonusers (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.36-0.84), controlling for age. When only never smokers without diabetes were assessed, the age-, lipid level-, and sex-adjusted OR was 0.40 (95% CI, 0.18-0.90). Five-year incidence of cortical cataract was 9.9% in statin users and 7.5% in nonusers (OR, 1.28; 95% CI, 0.79-2.08); posterior subcapsular cataract occurred in 3.0% of statin users and 3.4% of nonusers (OR, 0.82; 95% CI, 0.39-1.71). CONCLUSION: Statin use in a general population appears to be associated with lower risk of nuclear cataract, the most common type of age-related cataract.
CONTEXT: Statins are widely prescribed for their lipid-lowering effects but also have putative antioxidant properties. Oxidative stress is believed to play a role in the development of nuclear cataract, but little is known regarding the relationship of statin use and cataract incidence. OBJECTIVE: To evaluate the relationship of use of statins and incident cataract in adults in a midwestern community in the United States. DESIGN, SETTING, AND PARTICIPANTS: The Beaver Dam Eye Study, an observational, longitudinal, population-based study of age-related eye disease in Beaver Dam, Wis. There were 1299 persons who were seen at the third examination in 1998-2000, had gradable photographs in both eyes, and were deemed to be at risk of developing nuclear cataract within 5 years. MAIN OUTCOME MEASURE: Five-year incidence of cataract with respect to statin use. Cataracts were graded from photographs taken through the participant's dilated pupil. RESULTS: A total of 210 persons developed incident nuclear cataract in the interval from 1998-2000 to 2003-2005. Five-year incidence of nuclear cataract was 12.2% in statin users compared with 17.2% in nonusers (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.36-0.84), controlling for age. When only never smokers without diabetes were assessed, the age-, lipid level-, and sex-adjusted OR was 0.40 (95% CI, 0.18-0.90). Five-year incidence of cortical cataract was 9.9% in statin users and 7.5% in nonusers (OR, 1.28; 95% CI, 0.79-2.08); posterior subcapsular cataract occurred in 3.0% of statin users and 3.4% of nonusers (OR, 0.82; 95% CI, 0.39-1.71). CONCLUSION: Statin use in a general population appears to be associated with lower risk of nuclear cataract, the most common type of age-related cataract.
Authors: Shaza N Al-Holou; William R Tucker; Elvira Agrón; Traci E Clemons; Robert D Sperduto; Frederick L Ferris; Emily Y Chew Journal: Ophthalmology Date: 2015-12-11 Impact factor: 12.079
Authors: Amy Trentham-Dietz; Brian L Sprague; Ronald Klein; Barbara E K Klein; Karen J Cruickshanks; Dennis G Fryback; John M Hampton Journal: Breast Cancer Res Treat Date: 2007-08-03 Impact factor: 4.872
Authors: Yanjun Chen; David M Nondahl; Carla R Schubert; Barbara E K Klein; Ronald Klein; Karen J Cruickshanks Journal: Ophthalmic Epidemiol Date: 2017-01-31 Impact factor: 1.648
Authors: Yanjun Chen; David M Nondahl; Carla R Schubert; Dayna S Dalton; Adam J Paulsen; Barbara E K Klein; Ronald Klein; Karen J Cruickshanks Journal: Cogent Med Date: 2017-04-17
Authors: Jason L Sanders; Alessandro Iannaccone; Robert M Boudreau; Yvette P Conley; Patricia L Opresko; Wen-Chi Hsueh; Steven R Cummings; Richard M Cawthon; Tamara B Harris; Michael A Nalls; Steven B Kritchevsky; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2011-03-07 Impact factor: 6.053
Authors: Manuel B Datiles; Rafat R Ansari; Kwang I Suh; Susan Vitale; George F Reed; J Samuel Zigler; Frederick L Ferris Journal: Arch Ophthalmol Date: 2008-12